Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Home OCT Monitoring as a Safety Net for Early Detection of Recurrent Disease Activity in Neovascular Age-Related Macular Degeneration Under Standard Care.
Journal: Medicina (Kaunas, Lithuania)
Published: May 12, 2026
Geographic atrophy: From slowing lesions to preserving vision.
Journal: Current opinion in ophthalmology
Published: May 09, 2026
Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice.
Journal: Eye (London, England)
Published: February 05, 2026
Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy.
Journal: Journal of vitreoretinal diseases
Published: October 20, 2025
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: June 12, 2025
Reply to Comment on Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Journal: American journal of ophthalmology
Published: April 25, 2025
RWC Update: Intraocular Inflammation and Retinal Pharmacotherapy; Giant Retinal Tear; ILM Peeling in Myopic Macular Schisis.
Journal: Ophthalmic surgery, lasers & imaging retina
Published: March 11, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
Journal: Ophthalmology
Published: March 05, 2025
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.
Journal: Journal of vitreoretinal diseases
Published: March 03, 2025
Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series.
Journal: BMJ open ophthalmology
Published: December 19, 2024
Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Journal: American journal of ophthalmology
Published: December 09, 2024
Last Updated: 09/26/2026